{"id":"W2425777806","doi":"10.3747/co.23.3120","title":"Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Saint-Luc; Queen Elizabeth II Health Sciences Centre; University of Alberta; Occupational Cancer Research Centre; Ottawa Hospital; University Health Network; CancerCare Manitoba; McGill University; BC Cancer Agency; Hôpital Notre-Dame; Nova Scotia Health Authority; Royal Victoria Hospital; Sunnybrook Health Science Centre; Alberta Cancer Foundation; Jewish General Hospital; Juravinski Cancer Centre; University of Manitoba","funders":"Pfizer Canada; U.S. Food and Drug Administration; AstraZeneca","keywords":"Crizotinib; Anaplastic lymphoma kinase; Ceritinib; Medicine; Alectinib; Lung cancer; ALK inhibitor; Internal medicine; Oncology; Cancer research; ROS1; Targeted therapy; Population; Cancer; Adenocarcinoma","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009590751,0.0009253302,0.001984631,0.001983201,0.00509112,0.00345409,0.00798523,0.02205842,0.01020139],"category_scores_gemma":[0.01641434,0.0008175623,0.002678325,0.003069409,0.003077539,0.001876188,0.001870937,0.01463101,0.00892415],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02406054,"about_ca_system_score_gemma":0.117654,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.4381947,"about_ca_topic_score_gemma":0.6943738,"domain_scores_codex":[0.9875757,0.001329066,0.001667335,0.00072876,0.007102021,0.001596993],"domain_scores_gemma":[0.9477038,0.002641177,0.001630772,0.0007848965,0.03961473,0.007624635],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002875725,0.00001686692,0.0002085506,0.000319222,0.00001293115,0.0001513383,0.00003952373,0.0000719733,0.0002697796,0.0007044689,0.9778005,0.02037617],"study_design_scores_gemma":[0.00004284062,0.00001648183,0.0009853924,0.0006785326,0.00002314324,0.0002456846,0.00006623456,0.0000472757,0.0001931588,0.0005487753,0.9971265,0.00002600318],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.0008574747,0.07587671,0.001936389,0.7813077,0.07987788,0.0006261304,0.002400732,0.0002201992,0.05689682],"genre_scores_gemma":[0.02000163,0.1153505,0.01594155,0.6491306,0.03969556,0.0009289199,0.006577638,0.0003068983,0.1520668],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.5618053,"threshold_uncertainty_score":0.8712882,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02801169875360474,"score_gpt":0.3924874001777501,"score_spread":0.3644757014241453,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}